PSTV
Income statement / Annual
Last year (2024), Plus Therapeutics, Inc.'s total revenue was $5.82 M,
an increase of 18.54% from the previous year.
In 2024, Plus Therapeutics, Inc.'s net income was -$12.98 M.
See Plus Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$5.82 M |
$4.91 M |
$224.00 K |
$0.00 |
$303.00 K |
$7.00 M |
$2.98 M |
$6.41 M |
$11.38 M |
$11.66 M |
| Cost of Revenue |
$852.00 K
|
$9.69 M
|
$712.00 K
|
$66.00 K
|
$2.70 M
|
$5.37 M
|
$1.15 M
|
$1.32 M
|
$2.72 M
|
$3.19 M
|
| Gross Profit |
$4.97 M
|
-$4.78 M
|
-$488.00 K
|
-$66.00 K
|
-$2.40 M
|
$1.63 M
|
$1.84 M
|
$5.09 M
|
$8.67 M
|
$8.47 M
|
| Gross Profit Ratio |
0.85
|
-0.97
|
-2.18
|
0
|
-7.91
|
0.23
|
0.62
|
0.79
|
0.76
|
0.73
|
| Research and Development Expenses |
$10.58 M
|
$9.69 M
|
$9.70 M
|
$5.32 M
|
$3.48 M
|
$5.37 M
|
$5.52 M
|
$13.36 M
|
$16.20 M
|
$19.00 M
|
| General & Administrative Expenses |
$0.00
|
$8.54 M
|
$10.24 M
|
$6.85 M
|
$6.41 M
|
$4.82 M
|
$5.58 M
|
$7.59 M
|
$8.56 M
|
$9.77 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$468.00 K
|
$643.00 K
|
$3.59 M
|
$3.61 M
|
$2.66 M
|
| Selling, General & Administrative Expenses |
$9.09 M
|
$8.54 M
|
$10.24 M
|
$6.85 M
|
$6.41 M
|
$5.29 M
|
$6.22 M
|
$11.19 M
|
$12.17 M
|
$12.43 M
|
| Other Expenses |
$0.00
|
-$9.69 M
|
-$224.00 K
|
$250.00 K
|
$0.00
|
$0.00
|
-$1.15 M
|
$1.23 M
|
$0.00
|
-$7.67 M
|
| Operating Expenses |
$19.67 M
|
$8.54 M
|
$19.71 M
|
$12.43 M
|
$9.89 M
|
$10.66 M
|
$10.77 M
|
$25.78 M
|
$28.37 M
|
$31.43 M
|
| Cost And Expenses |
$20.52 M
|
$18.23 M
|
$19.94 M
|
$12.49 M
|
$9.89 M
|
$10.66 M
|
$11.75 M
|
$27.09 M
|
$31.09 M
|
$26.95 M
|
| Interest Income |
$273.00 K
|
$400.00 K
|
$147.00 K
|
$19.00 K
|
$50.00 K
|
$55.00 K
|
$43.00 K
|
$33.00 K
|
$19.00 K
|
$9.00 K
|
| Interest Expense |
$3.72 M
|
$395.00 K
|
$711.00 K
|
$932.00 K
|
$1.11 M
|
$1.86 M
|
$1.92 M
|
$2.05 M
|
$2.59 M
|
$3.38 M
|
| Depreciation & Amortization |
$852.00 K
|
$628.00 K
|
$619.00 K
|
$419.00 K
|
$369.00 K
|
$441.00 K
|
$2.00 M
|
$2.15 M
|
$1.18 M
|
$1.09 M
|
| EBITDA |
-$8.40 M |
-$12.69 M |
-$18.85 M |
-$12.05 M |
-$6.77 M |
-$987.00 K |
-$6.58 M |
-$18.49 M |
-$18.27 M |
-$14.27 M |
| EBITDA Ratio |
-1.44
|
-2.58
|
-84.16
|
0
|
-22.33
|
-0.14
|
-2.2
|
-2.88
|
-1.61
|
-1.22
|
| Operating Income Ratio |
-2.52
|
-2.71
|
-88
|
0
|
-31.63
|
-0.52
|
-2.94
|
-3.23
|
-1.73
|
-1.31
|
| Total Other Income/Expenses Net |
$1.72 M
|
$5.00 K
|
-$563.00 K
|
-$907.00 K
|
$1.34 M
|
$374.00 K
|
-$116.00 K
|
-$2.00 M
|
-$2.34 M
|
-$3.46 M
|
| Income Before Tax |
-$12.98 M
|
-$13.32 M
|
-$20.28 M
|
-$13.40 M
|
-$8.24 M
|
-$3.28 M
|
-$8.88 M
|
-$22.69 M
|
-$22.05 M
|
-$18.74 M
|
| Income Before Tax Ratio |
-2.23
|
-2.71
|
-90.51
|
0
|
-27.2
|
-0.47
|
-2.98
|
-3.54
|
-1.94
|
-1.61
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$12.98 M
|
-$13.32 M
|
-$20.28 M
|
-$13.40 M
|
-$8.24 M
|
-$10.89 M
|
-$12.63 M
|
-$22.69 M
|
-$22.05 M
|
-$18.74 M
|
| Net Income Ratio |
-2.23
|
-2.71
|
-90.51
|
0
|
-27.2
|
-1.56
|
-4.24
|
-3.54
|
-1.94
|
-1.61
|
| EPS |
-1.9544 |
-4.24 |
-11.55 |
-17.78 |
-27.9 |
-124.05 |
-1304.7 |
-5253.82 |
-9600 |
-14995.94 |
| EPS Diluted |
-2.3407 |
-4.24 |
-11.55 |
-17.78 |
-27.9 |
-138.1 |
-1304.7 |
-5253.82 |
-9600 |
-14995.94 |
| Weighted Average Shares Out |
$6.64 M
|
$3.14 M
|
$1.75 M
|
$804.74 K
|
$295.19 K
|
$92.27 K
|
$11.59 K
|
$431.86
|
$17.29 M
|
$140.80 M
|
| Weighted Average Shares Out Diluted |
$7.70 M
|
$3.14 M
|
$1.75 M
|
$805.95 K
|
$295.19 K
|
$92.27 K
|
$11.59 K
|
$431.86
|
$17.29 M
|
$140.80 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
